ABSTRACT
168

Statistical Analysis
169
The comparison of 6 groups of HSRA animals (S, C, and UNX8 with or without DOCA) 170 experimental data (proteinuria, blood pressure, etc.) was evaluated by one-way or two-way
171
ANOVA followed by either Dunnett's or Bonferroni (GraphPad Prism 6, La Jolla, CA). A p< 172 0.05 was considered to be statistically significant. All data are presented as mean + standard 173 error (SE).
174
RESULTS
175
Mean arterial pressure (MAP) steadily increased in all 3 groups of DOCA treated animals 176 from week 13-18 ( Fig. 2A) . DOCA+S rats exhibited a more rapid increase in MAP compared to 177 either the DOCA+UNX8 or DOCA+C groups, starting at week 15 (2 weeks post-treatment). By 178 week 18, the DOCA+S group demonstrated the highest MAP (192±5 mmHg), followed by 179 DOCA+UNX8 (173±3 mmHg) and DOCA+C (154±3 mmHg). Blood pressure for all 3 placebo groups remained essentially unchanged and ranged between 100 -110 mm Hg. Proteinuria increased before MAP for DOCA+S animals (week 14), but the increase in proteinuria was 182 concurrent with MAP for DOCA+UNX8. The DOCA+C group didn't exhibit any increase in 183 proteinuria over baseline or the Placebo+C group over the course of the experiment (Fig. 2B) .
184
By the end of the study (week 18), the DOCA+S groups exhibited the most severe proteinuria
185
(205±3 mg/24hr), which was 2.5 times more than that observed for the DOCA+UNX8 group
186
(76±3 mg/24hr). All other groups demonstrated no significant change in proteinuria from week 187 13-18 as all stayed below ~10 mg/24hr.
188
The increased blood pressure observed in the DOCA treated groups was corroborated by 189 increased cardiac hypertrophy compared to placebo groups (Fig. 3A) . Despite the DOCA+S 190 group demonstrating a greater rise in MAP compared to DOCA+UNX8, there was no significant 191 difference in heart weight/body weight (HW/BW) ratio (3.8±0.1 and 3.8±0.1, respectively).
192
However, both groups were significantly higher compared to DOCA+C (3.3±0.1) rats. There
193
were no significant differences in HW/BW observed between the 3 placebo groups (average 194 2.8±0.1). In general, histological findings in the heart showed a low degree of fibrosis, but there 195 were significant differences among groups ( Fig. 3B-C Renal hemodynamic measurements were performed at the end of the study (week 18) to 201 investigate the impact of increased systemic hypertension on renal blood flow (RBF) and 202 glomerular filtration rate (GFR). RBF (not corrected for kidney weight) was significantly increased in Placebo+S and Placebo+UNX8 rats compared to Placebo+C, but when corrected for 204 differences in kidney weight (KW) there were smaller differences between groups ( Fig. 4A-B ).
205
RBF (not corrected for kidney weight) was similar between DOCA+S (7.6±0.3 ul/min) 206 compared to DOCA+C (7.8±0.3ul/min) rats, whereas it was modestly increased in the 207 DOCA+UNX8 (9.0±0.5 ul/min) group (Fig. 4A) 
238
5A). The detected differences between groups in podocalyxin were similar to nephrin (Fig, 5B) .
239
However, significant differences between the DOCA+S and DOCA+UNX8 group (compared to 240 other groups) occurred earlier at week 13 and 15, respectively.
242
In addition to the examination of urinary biomarkers, renal injury was assessed by (Fig. 5C) . Kidneys from DOCA+S rats exhibited 247 significant renal hypertrophy (+1.3-fold) compared to the DOCA+UNX8 group (Fig. 5C ). The DOCA+UNX8 (+66.5%), and DOCA+C (+51.6%) compared to their respective placebo control.
251
Morphologically, DOCA-NaCl treatment had a significant impact on glomerular and 252 tubular injury between DOCA groups and placebo controls ( Fig. 5D and 6A-B using whole kidney ( Fig. 6C-D) . In the cortical region, kidneys from both DOCA+S
267
(10.1±0.7%) and DOCA+ UNX8 (9.2±1.3%) exhibited a similar level of fibrosis, but each were 268 significantly higher than the DOCA+C group (5.5±1.2%). In contrast, in the medulla, the 269 DOCA+S group (15.4±1.8%) exhibited 30% more fibrosis compared to DOCA+UNX8
270
(11.5±2.6%) rats (Fig. 7) .
No difference in macrophage or T-cell infiltration was observed among groups in the 273 absence of DOCA-NaCl treatment. Tubulointerstitial macrophage infiltration (CD68 positive 274 cells) was significantly increased (+17-fold) in kidney of DOCA+S compared to placebo animals 275 and +4.6 fold or +1.7 fold compared to DOCA+C and DOCA+UNX8, respectively (Fig. 8A) .
276
Kidneys from DOCA+S and DOCA+UNX8 also demonstrated an increase in T-cell infiltration and western blot analysis (CD-68 and TGFβ-1) ( Fig. 8C-D and salt retention compared DOCA+UNX8 (Fig. 10) . ( under baseline measurements of the HSRA model. In the current study, volume expansion likely increased the degree of hyperfiltration during the initial phase of DOCA-NaCl treatment.
341
Subsequently, this resulted in accelerated glomerular injury, reduced RBF, and GFR at only 18 342 weeks of age (5 weeks post treatment), whereas a similar degree of injury was previously 343 observed at much a later time (>month 12) in the absence of hypertension (Fig. 10) . ( (Fig. 10) .
347
The renal hemodynamic data (RBF and GFR) was presented both uncorrected and corrected 348 for differences in KW. one-kidney rats (S) and two-kidney littermates (C) were used for experiments. Two-kidney 531 control animals (littermates from S) were used to generate uninephrectomized animals (C 532 uninephrectomized at week 8; fully developed kidney and sexually mature). Spontaneous one-533 kidney rats exhibit ~20% less nephrons compared to individual kidney from two-kidney control. 
